Clinical significance of serum p53 antibodies in patients with ulcerative colitis and its carcinogenesis

Yoshizawa, Shigeo; Matsuoka, Katsuyoshi; Inoue, Nagamu; Takaishi, Hiromasa; Ogata, Haruhiko; Iwao, Yasushi; Mukai, Makio; Fujita, Toshio; Kawakami, Yutaka; Hibi, Toshifumi

doi:10.1002/ibd.20112

Cited by 24 publications

(16 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, OSMR methylation was not detected in any of 40 ulcerative colitis cases, indicating that its carcinogenesis pathway might be different from the polyps-carcinoma sequence pathway (23,24). This is consistent with the observations that ulcerative colitis-associated cancers showed less frequent CpG island methylator phenotype and higher p53 mutation rates than sporadic colorectal cancers (25,26).…”

Section: Discussionsupporting

confidence: 87%

“…In the present study, OSMR methylation was frequently observed in colorectal polyps, including hyperplastic polyps (100%), serrated adenoma (90%), tubulovillous adenoma (100%), and tubular adenoma (63%), indicating that OSMR methylation occurs early in colorectal carcinogenesis. Patients with ulcerative colitis have been reported to be at increased risk for developing colorectal cancer due to repetitive mucosal injury (25,26). However, OSMR methylation was not detected in any of 40 ulcerative colitis cases, indicating that its carcinogenesis pathway might be different from the polyps-carcinoma sequence pathway (23,24).…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Unique Methylation Pattern of Oncostatin M Receptor Gene in Cancers of Colorectum and Other Digestive Organs

Deng

Kakar²,

Okudiara³

et al. 2009

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Oncostatin M (OSM) is an interleukin-6 cytokine family member, which inhibits cell proliferation and induces cell differentiation and apoptosis in cancers. In melanoma cells, epigenetic silencing of OSM receptor (OSMR) by histone deacetylation contributes to escape of cell growth control by OSM. However, the silencing of OSMR by DNA methylation in any cancer has not been examined. Experimental Design: Methylation status of OSMR was determined by sequencing or methylation-specific PCR in primary tumors and cell lines. Cell lines were treated with DNA methyltransferase inhibitors 5-aza-2-deoxycytidine or DNA methyltransferase 1 small interfering RNA or a histone deacetylase inhibitor trichostatin A. OSMR mRNA level was determined by reverse transcription-PCR.The acetylation of histone H3 was analyzed by chromatin immunoprecipitation assay. Results: We observed methylation of OSMR in 88 of 98 (90%) colorectal cancers, 34 of 38 (89%) colorectal polyps, 17 of 31 (55%) normal-appearing mucosa adjacent to colorectal cancers, 13 of 40 (33%) gastric cancers, and 2 of 10 (20%) pancreatic cancers. OSMR methylation was absent or rarely detected in normal colonic mucosa from noncancer patients or in cancers of nondigestive organs, including breast, lung, liver, prostate, kidney, and melanoma. We observed a significant correlation between OSMR methylation and loss of mRNA expression in 39 cancer cell lines. Following the treatment of colorectal cancer cell lines with 5-aza-2-deoxycytidine, DNA methyltransferase 1small interfering RNA, or trichostatin A, the induction of OSMR mRNA and the enrichment in the level of histone acetylation were observed. Conclusions: The epigenetic silencing and DNA methylation of OSMR occur frequently in colorectal cancers and rarely in cancers of nondigestive organs. OSMR methylation is an early event in the colorectal carcinogenesis.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 98%

Unique Methylation Pattern of Oncostatin M Receptor Gene in Cancers of Colorectum and Other Digestive Organs

Deng

Kakar²,

Okudiara³

et al. 2009

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Studies have shown that autoantibodies to p53 can help identify individuals at increased risk of developing colorectal cancer as these autoantibodies have been detected in patients with precancerous colorectal cancer lesions. In fact, the screening for these autoantibodies is suggested in addition to colonoscopy screens (95)(96)(97). However, antibodies to p53 have also been associated with a range of other cancers, which reduces the specificity of this biomarker for colon cancer.…”

Section: Colon Cancermentioning

confidence: 99%

Serologic Autoantibodies as Diagnostic Cancer Biomarkers—A Review

Zaenker

Ziman

2013

Cancer Epidemiology, Biomarkers &Amp; Prevention

134

111

View full text Add to dashboard Cite

Current diagnostic techniques used for the early detection of cancers are successful but subject to detection bias. A recent focus lies in the development of more accurate diagnostic tools. An increase in serologic autoantibody levels has been shown to precede the development of cancer disease symptoms. Therefore, autoantibody levels in patient blood serum have been proposed as diagnostic biomarkers for early-stage diagnosis of cancers. Their clinical application has, however, been hindered by low sensitivity, specificity, and low predictive value scores. These scores have been shown to improve when panels of multiple diagnostic autoantibody biomarkers are used. A five-marker biomarker panel has been shown to increase the sensitivity of prostate cancer diagnosis to 95% as compared with 12.2% for prostate-specific antigen alone. New potential biomarker panels were also discovered for lung, colon, and stomach cancer diagnosis with sensitivity of 76%, 65.4%, and 50.8%, respectively. Studies in breast and liver cancer, however, seem to favor single markers, namely a-2-HS-glycoprotein and des-g-carboxyprothrombin with sensitivities of 79% and 89% for the early detection of the cancers. The aim of this review is to discuss the relevance of autoantibodies in cancer diagnosis and to outline the current methodologies used in the detection of autoantibodies. The review concludes with a discussion of the autoantibodies currently used in the diagnosis of cancers of the prostate, breast, lung, colon, stomach, and liver. A discussion of the potential future use of autoantibodies as diagnostic cancer biomarkers is also included in this review. Cancer Epidemiol Biomarkers Prev; 22(12); 2161-81. Ó2013 AACR.

show abstract

“…Patel et al went even further to develop an autoantibody "direct-capture" immunobead assay using selected antigens for successful detection of nonsmall-cell lung carcinoma with a sensitivity and specificity of 94% and 97%, respectively (Patel et al, 2011). Similar advances using panels of autoantibodies have been made for the diagnosis of colon cancer (Belousov et al, 2008;Chen et al, 2007;Cioffi et al, 2004;Yoshizawa et al, 2007), stomach cancer (di Mario & Cavallaro, 2008), and hepatocellular carcinoma (Li, Chen, Yu, Li, & Wang, 2008;Marrero et al, 2003). Studies have demonstrated that the successful development of a single autoantibody biomarker approach for disease diagnostics has so far been hampered by low sensitivity, specificity, and predictive values, as well as poor reproducibility in larger sample cohorts.…”

Section: Autoantibodies In Cancer: Byproduct or Biomarker?mentioning

confidence: 92%

Utility of Autoantibodies as Biomarkers for Diagnosis and Staging of Neurodegenerative Diseases

DeMarshall

Sarkar

Nägele

et al. 2015

International Review of Neurobiology

View full text Add to dashboard Cite

Clinical significance of serum p53 antibodies in patients with ulcerative colitis and its carcinogenesis

Cited by 24 publications

References 43 publications

Unique Methylation Pattern of Oncostatin M Receptor Gene in Cancers of Colorectum and Other Digestive Organs

Unique Methylation Pattern of Oncostatin M Receptor Gene in Cancers of Colorectum and Other Digestive Organs

Serologic Autoantibodies as Diagnostic Cancer Biomarkers—A Review

Utility of Autoantibodies as Biomarkers for Diagnosis and Staging of Neurodegenerative Diseases

Contact Info

Product

Resources

About